Exercise Mediates Myokine Release and Tumor Suppression in Prostate Cancer Independent of Androgen Signaling.
Journal
Exercise and sport sciences reviews
ISSN: 1538-3008
Titre abrégé: Exerc Sport Sci Rev
Pays: United States
ID NLM: 0375434
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
11
9
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
A prominent toxicity of androgen suppression in patients with prostate cancer (PCa) is loss of skeletal muscle. Exercise may induce tumor suppression through the endocrinal function of skeletal muscle; however, this is currently unknown. In this review, we summarize our work demonstrating the acute and chronic myokine response to exercise and the tumor-suppressive effect of circulatory milieu alteration in PCa patients.
Identifiants
pubmed: 37288965
doi: 10.1249/JES.0000000000000323
pii: 00003677-990000000-00025
doi:
Substances chimiques
Androgens
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-168Informations de copyright
Copyright © 2023 by the American College of Sports Medicine.
Références
Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res . 1994; 54(20):5474–8.
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer . 2001; 1(1):34–45.
Datta D, Aftabuddin M, Gupta DK, Raha S, Sen P. Human prostate cancer hallmarks map. Sci. Rep . 2016; 6:30691.
Mostaghel EA, Montgomery B, Nelson PS. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol. Oncol . 2009; 27(3):251–7.
Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J. Natl. Compr. Canc. Netw . 2010; 8(2):211–23.
Schmitz KH, Campbell AM, Stuiver MM, et al. Exercise is medicine in oncology: engaging clinicians to help patients move through cancer. CA Cancer J. Clin . 2019; 69(6):468–84.
Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res . 2011; 71(11):3889–95.
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J. Clin. Oncol . 2011; 29(6):726–32.
Pak S, Kim MS, Park EY, Kim SH, Lee KH, Joung JY. Association of body composition with survival and treatment efficacy in castration-resistant prostate cancer. Front. Oncol . 2020; 10:558.
Lopez P, Taaffe DR, Newton RU, Galvao DA. Resistance exercise dosage in men with prostate cancer: systematic review, meta-analysis, and meta-regression. Med. Sci. Sports Exerc . 2021; 53(3):459–69.
Kim J-S, Galvão DA, Newton RU, Gray E, Taaffe DR. Exercise-induced myokines and their effect on prostate cancer. Nat. Rev. Urol . 2021; 18(9):519–42.
Fiuza-Luces C, Garatachea N, Berger NA, Lucia A. Exercise is the real polypill. Physiology (Bethesda) . 2013; 28(5):330–58.
Pedersen BK. The physiology of optimizing health with a focus on exercise as medicine. Annu. Rev. Physiol . 2019; 81:607–27.
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol . 2012; 8(8):457–65.
Dubois V, Laurent M, Boonen S, Vanderschueren D, Claessens F. Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions. Cell. Mol. Life Sci . 2012; 69(10):1651–67.
Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst . 2001; 93(22):1687–97.
Lindzey J, Kumar MV, Grossman M, Young C, Tindall DJ. Molecular mechanisms of androgen action. Vitam. Horm . 1994; 49:383–432.
Saad F, Efstathiou E, Attard G, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol . 2021; 22(11):1541–59.
Joubert Y, Tobin C. Satellite cell proliferation and increase in the number of myonuclei induced by testosterone in the levator ani muscle of the adult female rat. Dev. Biol . 1989; 131(2):550–7.
Joubert Y, Tobin C, Lebart MC. Testosterone-induced masculinization of the rat levator ani muscle during puberty. Dev. Biol . 1994; 162(1):104–10.
Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am. J. Physiol. Endocrinol. Metab . 2003; 285(1):E197–205.
Semirale AA, Zhang XW, Wiren KM. Body composition changes and inhibition of fat development in vivo implicates androgen in regulation of stem cell lineage allocation. J. Cell. Biochem . 2011; 112(7):1773–86.
Ophoff J, Van Proeyen K, Callewaert F, et al. Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology . 2009; 150(8):3558–66.
Woodhouse LJ, Gupta N, Bhasin M, et al. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J. Clin. Endocrinol. Metab . 2004; 89(2):718–26.
Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab . 2002; 87(2):599–603.
Galvão DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int . 2008; 102(1):44–7.
Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J. Clin. Oncol . 2010; 28(2):340–7.
Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvao DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis . 2013; 16(4):328–35.
Cormie P, Galvão DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int . 2015; 115(2):256–66.
Nilsen TS, Raastad T, Skovlund E, et al. Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy. Acta Oncol . 2015; 54(10):1805–13.
Wall BA, Galvão DA, Fatehee N, et al. Exercise improves V˙O 2max and body composition in androgen deprivation therapy–treated prostate cancer patients. Med. Sci. Sports Exerc . 2017; 49(8):1503–10.
Gilbert SE, Tew GA, Fairhurst C, et al. Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer. Br. J. Cancer . 2016; 114(4):401–8.
Newton RU, Galvão DA, Spry N, et al. Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients. Med. Sci. Sports Exerc . 2019; 51(4):607–14.
Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer . 2018; 18(1):368.
Gunnell AS, Joyce S, Tomlin S, et al. Physical activity and survival among long-term cancer survivor and non-cancer cohorts. Front. Public Health . 2017; 5:19.
Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate . 2003; 56(3):201–6.
Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology . 2003; 144(6):2319–24.
Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J. Appl. Physiol . 2004; 96(2):450–4.
Rundqvist H, Augsten M, Stromberg A, et al. Effect of acute exercise on prostate cancer cell growth. PloS One . 2013; 8(7):e67579.
Hwang JH, McGovern J, Minett GM, et al. Mobilizing serum factors and immune cells through exercise to counteract age-related changes in cancer risk. Exerc. Immunol. Rev . 2020; 26:80–99.
Kang DW, Fairey AS, Boule NG, Field CJ, Wharton SA, Courneya KS. Effects of exercise on cardiorespiratory fitness and biochemical progression in men with localized prostate cancer under active surveillance: the ERASE randomized clinical trial. JAMA Oncol . 2021; 7(10):1487–95.
Kim JS, Wilson RL, Taaffe DR, Galvao DA, Gray E, Newton RU. Myokine expression and tumor-suppressive effect of serum after 12 wk of exercise in prostate cancer patients on ADT. Med. Sci. Sports Exerc . 2021; 54(2):197–205.
Kim JS, Taaffe DR, Galvão DA, et al. Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer Prostatic Dis . 2022; 25(1):86–92.
Kim JS, Taaffe DR, Galvão DA, et al. Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer. Prostate Cancer Prostatic Dis . 2022. doi:10.1038/s41391-022-00624-4.
doi: 10.1038/s41391-022-00624-4
Said N, Frierson HF Jr., Chernauskas D, Conaway M, Motamed K, Theodorescu D. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene . 2009; 28(39):3487–98.
Shin M, Mizokami A, Kim J, et al. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. Prostate . 2013; 73(11):1159–70.
Hu Y, Sun H, Owens RT, et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia . 2009; 11(10):1042–53.
Xu W, Neill T, Yang Y, et al. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther . 2015; 22(3):247–56.
Tekin S, Erden Y, Sandal S, Yilmaz B. Is irisin an anticarcinogenic peptide? Med-Science . 2015; 4(2):2172–80.
Dai H, Hu W, Zhang L, et al. FGF21 facilitates autophagy in prostate cancer cells by inhibiting the PI3K-Akt-mTOR signaling pathway. Cell Death Dis . 2021; 12(4):303.
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature . 1997; 387(6628):83–90.
Reisz-Porszasz S, Bhasin S, Artaza JN, et al. Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am. J. Physiol. Endocrinol. Metab . 2003; 285(4):E876–88.
Singh R, Bhasin S, Braga M, et al. Regulation of myogenic differentiation by androgens: cross talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-beta signaling pathways. Endocrinology . 2009; 150(3):1259–68.
Iemura S, Kawao N, Okumoto K, Akagi M, Kaji H. Role of irisin in androgen-deficient muscle wasting and osteopenia in mice. J. Bone Miner. Metab . 2020; 38(2):161–71.
Aslan R, Alp HH, Eryilmaz R, et al. Can the irisin be a biomarker for prostate cancer? A case control study. Asian Pac. J. Cancer Prev . 2020; 21(2):505–9.
Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med. Sci. Sports Exerc . 2019; 51(11):2375–90.
Hayes SC, Newton RU, Spence RR, Galvão DA. The Exercise and Sports Science Australia position statement: exercise medicine in cancer management. J. Sci. Med. Sport . 2019; 22(11):1175–99.
Newton RU, Kenfield SA, Hart NH, et al. Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open . 2018; 8(5):e022899.
Dethlefsen C, Lillelund C, Midtgaard J, et al. Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses. Breast Cancer Res. Treat . 2016; 159(3):469–769.